<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; RA</title>
	<atom:link href="http://www.stockbloghub.com/tag/ra/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(VRTX) Vertex Pharmaceuticals Reports Positive Data</title>
		<link>http://www.stockbloghub.com/2011/09/12/vrtx-vertex-pharmaceuticals-reports-positive-data/82979</link>
		<comments>http://www.stockbloghub.com/2011/09/12/vrtx-vertex-pharmaceuticals-reports-positive-data/82979#comments</comments>
		<pubDate>Mon, 12 Sep 2011 17:19:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BID]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[RA]]></category>
		<category><![CDATA[Railamerica Inc]]></category>
		<category><![CDATA[Sotheby's]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82979</guid>
		<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) reported positive data from a mid-stage trial on VX-509, which is being studied for the treatment of moderate to severe rheumatoid arthritis (RA). The 12-week study, which evaluated four doses of the candidate, met both the primary endpoints. Data from the two highest dose (100 mg and 150 mg) treatment arms demonstrated significant improvement in the proportion of people who achieved at least a 20% improvement in the signs and symptoms of RA (ACR20), and a statistically significant improvement from baseline in Disease Activity Score 28 (DAS28), compared to placebo. The study also met the secondary endpoints (ACR50 and ACR70) of achieving statistically significant responses compared to placebo. On the basis of the data from the phase IIa study, Vertex Pharma plans to initiate a six-month ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/12/vrtx-vertex-pharmaceuticals-reports-positive-data/82979/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SCR) Simcere Drug Cleared in China</title>
		<link>http://www.stockbloghub.com/2011/09/01/scr-simcere-drug-cleared-in-china/82262</link>
		<comments>http://www.stockbloghub.com/2011/09/01/scr-simcere-drug-cleared-in-china/82262#comments</comments>
		<pubDate>Thu, 01 Sep 2011 17:26:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RA]]></category>
		<category><![CDATA[Railamerica Inc]]></category>
		<category><![CDATA[SCR]]></category>
		<category><![CDATA[Simcere Pharmaceutical Group.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82262</guid>
		<description><![CDATA[Recently, the State Food and Drug Administration (SFDA) of China delivered a boost to Simcere Pharmaceutical Group (SCR) by clearing its drug Iremod, for treating patients suffering from active rheumatoid arthritis (RA). Iremod, developed solely by Simcere, will be the first Iguratimod drug to hit the global market and will be used mainly to treat patients suffering from active RA. Iguratimod refers to a new disease-modifying, anti-rheumatoid therapy and belongs to the category of Disease Modifying Anti-rheumatic Drugs (DMARDs). The approval of Iremod by the Chinese regulatory authorities will not only boost Simcere’s top line but also widen the treatment options for patients suffering from the dreaded disease, whose incidence is on the rise. Iremod will operate in a highly lucrative market and will compete with players like Bristol-Myers (BMY), ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/01/scr-simcere-drug-cleared-in-china/82262/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(REGN) Regeneron Pharmaceuticals Gets Mixed Data for REGN88</title>
		<link>http://www.stockbloghub.com/2011/07/14/regn-regeneron-pharmaceuticals-gets-mixed-data-for-regn88/79111</link>
		<comments>http://www.stockbloghub.com/2011/07/14/regn-regeneron-pharmaceuticals-gets-mixed-data-for-regn88/79111#comments</comments>
		<pubDate>Thu, 14 Jul 2011 21:30:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Minerals Technologies Inc.]]></category>
		<category><![CDATA[MTX]]></category>
		<category><![CDATA[RA]]></category>
		<category><![CDATA[Railamerica Inc]]></category>
		<category><![CDATA[Regeneron Pharmaceuticals Inc]]></category>
		<category><![CDATA[REGN]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79111</guid>
		<description><![CDATA[Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi Aventis (SNY) recently announced data from two mid-stage studies of their pipeline candidate sarilumab (REGN88/SAR153191). While one study (MOBILITY) evaluated patients with rheumatoid arthritis (RA) the other (ALIGN) evaluated ankylosing spondylitis (AS) patients. Sarilumab is an antibody targeting the interleukin-6 receptor (IL-6R). The data from the RA trial was positive while the AS trial data was not too encouraging. The MOBILITY (n=306) trial showed that sarilumab in combination with methotrexate (MTX), the standard of care for RA, led to significant improvement in signs and symptoms of moderate-to-severe RA patients versus patients treated with MTX plus placebo. The trial compared 5 doses of sarilumab plus MTX to placebo plus MTX. 49% of patients receiving the lowest dose met the primary endpoint of at least ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/14/regn-regeneron-pharmaceuticals-gets-mixed-data-for-regn88/79111/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Labs Boosts Immunology Pipeline</title>
		<link>http://www.stockbloghub.com/2011/06/24/abt-abbott-labs-boosts-immunology-pipeline/77422</link>
		<comments>http://www.stockbloghub.com/2011/06/24/abt-abbott-labs-boosts-immunology-pipeline/77422#comments</comments>
		<pubDate>Fri, 24 Jun 2011 22:04:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RA]]></category>
		<category><![CDATA[Railamerica Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77422</guid>
		<description><![CDATA[Abbott Labs (ABT) recently entered into a global agreement with Biotest AG for the development and commercialization of a novel anti-CD4 antibody, BT-061. The Candidate: BT-061 The deal is focused on the development and commercialization of BT-061 for the treatment of rheumatoid arthritis (RA) and psoriasis. BT-061 is currently being evaluated in phase II studies for RA and psoriasis. Moreover, the candidate’s potential to be used for other immune-related diseases is being evaluated in preclinical studies. BT-061 could be differentiated from other anti-CD4 antibodies as it does not cause depletion of CD4 positive T-cells which would lead to weakened immune responses. Terms of the Deal Per the terms of the agreement, BT-061 will be co-promoted by Abbott Labs and Biotest in the five major European markets: Germany, France, United Kingdom, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/abt-abbott-labs-boosts-immunology-pipeline/77422/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BRKA) U.S. Rail Industry Outlook &#8211; June 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/06/15/brka-u-s-rail-industry-outlook-june-2010-industry-outlook/40500</link>
		<comments>http://www.stockbloghub.com/2010/06/15/brka-u-s-rail-industry-outlook-june-2010-industry-outlook/40500#comments</comments>
		<pubDate>Tue, 15 Jun 2010 17:53:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Property & Casualty Insurance]]></category>
		<category><![CDATA[Berkshire Hathaway]]></category>
		<category><![CDATA[BRKA]]></category>
		<category><![CDATA[BRKB]]></category>
		<category><![CDATA[Canadian National Railway Company]]></category>
		<category><![CDATA[Canadian Pacific Railway Limited]]></category>
		<category><![CDATA[CNI]]></category>
		<category><![CDATA[CP]]></category>
		<category><![CDATA[CSX]]></category>
		<category><![CDATA[CSX Corporation]]></category>
		<category><![CDATA[Kansas City Southern]]></category>
		<category><![CDATA[KSU]]></category>
		<category><![CDATA[Norfolk Southern Corporation]]></category>
		<category><![CDATA[NSC]]></category>
		<category><![CDATA[RA]]></category>
		<category><![CDATA[Railamerica Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=40500</guid>
		<description><![CDATA[Along with all other industries in the U.S., railroads also suffered during the economic downturn. Freight rail is a “derived demand&#8221; industry &#8212; demand for the rail service is tied with demand for the products that the railroads haul. Rail traffic, therefore, acts as a solid barometer of the overall health of the economy. Since around 2003?2004, a number of factors have led to an increase in rail freight volume in the U.S: Rising fuel costs led to an increased demand for rail, since railroads are on an average four times more fuel-efficient than trucks. A surge in U.S. imports and record U.S. agricultural exports boosted rail shipments to and from ports. A rise in natural gas prices caused power plants to burn more coal to generate electricity, and most ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/06/15/brka-u-s-rail-industry-outlook-june-2010-industry-outlook/40500/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Johnson and Johnson Sees Encouraging Phase III Data</title>
		<link>http://www.stockbloghub.com/2009/11/23/jnj-johnson-and-johnson-sees-encouraging-phase-iii-data/21132</link>
		<comments>http://www.stockbloghub.com/2009/11/23/jnj-johnson-and-johnson-sees-encouraging-phase-iii-data/21132#comments</comments>
		<pubDate>Tue, 24 Nov 2009 05:57:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[RA]]></category>
		<category><![CDATA[Railamerica Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21132</guid>
		<description><![CDATA[Johnson and Johnson (JNJ) recently presented long-term data from two phase III clinical trials of Simponi (golimumab), carried out on rheumatoid arthritis (RA) patients. It was observed that patients taking Simponi every four weeks achieved sustained improvements through one year. The data were presented at the 2009 American College of Rheumatology (ACR) Annual Scientific Meeting held last month. Data from the first trial – GOlimumab After Former anti-TNF (tumor necrosis factor) Therapy Evaluated in RA (GO-AFTER) revealed that patients previously treated with TNF inhibitors (adalimumab, etanercept or infliximab) responded as well as showed continued response to the drug for an entire year. At week 52, data measured by American College of Rheumatology (ACR 20) response found a 20% improvement in arthritis symptoms in 63% of patients receiving the drug while ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/23/jnj-johnson-and-johnson-sees-encouraging-phase-iii-data/21132/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RA) RailAmerica IPO Debuts</title>
		<link>http://www.stockbloghub.com/2009/10/16/ra-railamerica-ipo-debuts/17813</link>
		<comments>http://www.stockbloghub.com/2009/10/16/ra-railamerica-ipo-debuts/17813#comments</comments>
		<pubDate>Fri, 16 Oct 2009 22:34:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Railroads]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[RA]]></category>
		<category><![CDATA[Railamerica Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17813</guid>
		<description><![CDATA[Following the closure of its initial public offering (IPO), RailAmerica (RA) has started trading under the ticker symbol “RA&#8221; on New York Stock Exchange since Tuesday. RailAmerica, which filed for IPO in late July, had offered 10.5 million primary shares and 11.5 million secondary shares priced at $15 per share last week. It had expected them to price for between $16 and $18. The company intends to use the proceeds of $144 million from issuing 10.5 million primary shares for paying off debt and other corporate purposes. The shares, which started trading on Tuesday, fell by approximately 8.2%. A number of private equity companies that unloaded their portfolio companies recently have realized gains less than expected. Rail America is a portfolio company that was bought by Fortress Investment Group in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/16/ra-railamerica-ipo-debuts/17813/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

